{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:16:40Z","timestamp":1788365800314,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.016","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:02:14Z","timestamp":1781200934000},"page":"5243-5256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Azidothymidine potentiates the immunomodulatory function of interferon-\u03b1 in adult T cell leukemia\/lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Xiaoyi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-7201","authenticated-orcid":false,"given":"Guangyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.016_bib1","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","article-title":"Interferons in health and disease","volume":"188","author":"Boehmer","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.016_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12863","article-title":"Interferon alpha in cancer immunoediting: From elimination to escape","volume":"91","author":"Vidal","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.016_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons alpha and beta in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.06.016_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.06.016_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jhep.2006.07.032","article-title":"Role of the Fas\/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro","volume":"46","author":"Nakamura","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)61921-8","article-title":"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04\/EORTC GU 30012): an open-label randomised trial","volume":"375","author":"Gore","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.06.016_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/CMR.0b013e3283390365","article-title":"A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma","volume":"20","author":"Vihinen","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ymthe.2026.06.016_bib9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2026.06.016_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00128072-200204080-00004","article-title":"Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection","volume":"4","author":"Bhana","year":"2002","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ymthe.2026.06.016_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/infdis\/169.6.1351","article-title":"Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection","volume":"169","author":"Frissen","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.06.016_bib12","first-page":"77","article-title":"Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068","volume":"1","author":"Mildvan","year":"1996","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ymthe.2026.06.016_bib13","first-page":"101","article-title":"Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia","volume":"5","author":"Estrov","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.06.016_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-111-4-280","article-title":"Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)","volume":"111","author":"Kovacs","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0140-6736(05)65260-9","article-title":"Azothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma","volume":"348","author":"Harrington","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.06.016_bib16","first-page":"5514","article-title":"Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas","volume":"59","author":"Lee","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.016_bib17","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fmicb.2020.01062","article-title":"Novel Treatments of Adult T Cell Leukemia Lymphoma","volume":"11","author":"El Hajj","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12985-023-02077-0","article-title":"Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia\/lymphoma (ATLL): a systematic review and meta-analysis","volume":"20","author":"Shafiee","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2026.06.016_bib20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-111-11-871","article-title":"Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1)","volume":"111","author":"Shibata","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2014.02.021","article-title":"Prevalence of human T-lymphotropic virus type 1 infection among blood donors in mainland China: a meta-analysis","volume":"25","author":"Li","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.06.016_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological Aspects and World Distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib24","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.016_bib25","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3390\/jcm9082417","article-title":"Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia\/Lymphoma-Romanian Experience","volume":"9","author":"Tanase","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib27","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib28","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0168-1702(01)00285-4","article-title":"Efficacy of 3'-azido 3'deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells","volume":"78","author":"Zhang","year":"2001","journal-title":"Virus. Res."},{"key":"10.1016\/j.ymthe.2026.06.016_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-4690-10-52","article-title":"Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells","volume":"10","author":"Kinpara","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymthe.2026.06.016_bib31","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2006-07-036368","article-title":"IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia\/lymphoma","volume":"109","author":"Ramos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.016_bib32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3109\/10428191003728628","article-title":"Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha","volume":"51","author":"Alizadeh","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2026.06.016_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","article-title":"A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies","volume":"35","author":"Hermine","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2026.06.016_bib34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/sj.leu.2401742","article-title":"Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia\/lymphoma","volume":"14","author":"Bazarbachi","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.06.016_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28424","article-title":"HTLV-1 persistent infection and ATLL oncogenesis","volume":"95","author":"Zuo","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1013381","article-title":"Splicing-dependent restriction of the HBZ gene by Tax underlies biphasic HTLV-1 infection","volume":"21","author":"Liang","year":"2025","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.06.016_bib37","article-title":"Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia","volume":"122","author":"Liu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.016_bib38","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.4049\/jimmunol.1500204","article-title":"ATF3 Is a Key Regulator of Macrophage IFN Responses","volume":"195","author":"Labzin","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","article-title":"Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons","volume":"51","author":"Forero","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.06.016_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/pathogens13010087","article-title":"HTLV-1 Tax Tug-of-War: Cellular Senescence and Death or Cellular Transformation","volume":"13","author":"Bellon","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ymthe.2026.06.016_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00405-24","article-title":"The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7","volume":"98","author":"Bellon","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014783118","article-title":"Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence","volume":"118","author":"Ma","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.016_bib43","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1038\/s41467-020-17644-0","article-title":"Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer","volume":"11","author":"Buqu\u00e9","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.016_bib44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12967-022-03454-z","article-title":"Nicotinamide drives T cell activation in the mammary tumor microenvironment","volume":"20","author":"Hu","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib45","doi-asserted-by":"crossref","first-page":"e001250","DOI":"10.1136\/jitc-2020-001250","article-title":"Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice","volume":"8","author":"Selvanesan","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.016_bib46","article-title":"Amino-acid transporters in T-cell activation and differentiation","volume":"8","author":"Ren","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2026.06.016_bib47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ni.2556","article-title":"Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation","volume":"14","author":"Sinclair","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1643017","article-title":"Glutamine metabolism and ammonia death: targeted modulation for enhanced cancer immunotherapy","volume":"16","author":"Du","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib49","article-title":"Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib50","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4161\/auto.21315","article-title":"Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes","volume":"8","author":"Garc\u00eda-Navas","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2026.06.016_bib51","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2026.06.016_bib52","doi-asserted-by":"crossref","first-page":"e002840","DOI":"10.1136\/jitc-2021-002840","article-title":"Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation","volume":"9","author":"Qin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.016_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150472","article-title":"HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia\/lymphoma","volume":"131","author":"Tan","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.06.016_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001117","article-title":"HLA class I binding of HBZ determines outcome in HTLV-1 infection","volume":"6","author":"Macnamara","year":"2010","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.06.016_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-4690-10-91","article-title":"The combination of arsenic, interferon-alpha, and zidovudine restores an \u201csimmunocompetent-like\u201d cytokine expression profile in patients with adult T-cell leukemia lymphoma","volume":"10","author":"Kchour","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymthe.2026.06.016_bib56","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/AAC.31.12.1972","article-title":"3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase","volume":"31","author":"St Clair","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2026.06.016_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients","volume":"113","author":"Matutes","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2026.06.016_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol. J."},{"key":"10.1016\/j.ymthe.2026.06.016_bib59","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10428190601071717","article-title":"Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran","volume":"48","author":"Kchour","year":"2007","journal-title":"Leuk. Lymphoma"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:23:21Z","timestamp":1788362601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626004934"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azidothymidine potentiates the immunomodulatory function of interferon-\u03b1 in adult T cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}